Survival after stereotactic radiotherapy in patients with early-stage non-small cell lung cancer

Figures & data

Table 1. Patient characteristics.

	≤69 years N = 176	70–74 years N = 115	75–79 years N = 131	≥80 years N = 122	Total N = 544
Age (median years)	65.1	72.9	77.5	83.7	74.4
Sex
Female	105 (60%)	62 (54%)	75 (57%)	48 (39%)	290 (53%)
Male	71 (40%)	53 (45%)	56 (43%)	74 (61%)	254 (47%)
Performance status
0–1	98 (56%)	53 (46%)	66 (50%)	54 (44%)	271 (50%)
2–3^b	88 (44%)^b	62 (54%)	65 (50%)	68 (56%)	273 (50%)^b
Charlson CI
0	29 (17%	6 (5%)	17 (13%)	11 (25%)	63 (12%)
1	52 (30%)	32 (28%)	43 (33%)	31 (25%)	158 (29%)
2	36 (21%)	32 (28%)	21 (16%)	28 (23%)	117 (22%)
3+	59 (34%)	45 (39%)	50 (38%)	52 (43%)	206 (38%)
Body mass index
<18.5 kg/cm^2	23 (13%)	16 (14%)	13 (10%)	14 (12%)	66 (12%)
≥18.5 kg/cm^2	151 (86%)	98 (85%)	117 (89%)	106 (87%)	472 (87%)
Missing data
Smoking habits	2 (1%)	1 (1%)	1 (1%)	2 (2%)	6 (1%)
Never smoker	2 (1%)	1 (1%)	6 (5%)	2 (2%)	11 (2%)
Quitter ≥10 years	19 (11%)	26 (23%)	33 (25%)	47 (19%)	125 (23%)
Quitter 1–10 years	52 (30%)	28 (24%)	27 (21%)	24 (20%)	131 (24%)
Smoker within last year	103 (59%)	60 (52%)	65 (50%)	49 (40%)	277 (51%)
FEV1 of predicted value^a
<50%	70 (40%)	54 (47%)	29 (22%)	28 (23%)	181 (33%)
50% to <80%	74 (42%)	51 (44%)	63 (49%)	51 (42%)	239 (44%)
≥80%	32 (18%)	10 (9%)	38 (29%)	43 (35%)	123 (23%)
Previous lung resection
None	138 (78%)	105 (91%)	111 (85%)	109 (89%)	463 (85%)
Resection	9 (5%)	2 (2%)	7 (5%)	6 (5%)	24 (4%)
Lobectomy	26 (15%)	8 (7%)	13 (10%)	6 (5%)	53 (10%)
Pneumonectomy	3 (2%)	0 (0%)	0 (0%)	1 (1%)	4 (1%)
Histology
Squamous	40 (23%)	37 (32%)	43 (33%)	50 (41%)	170 (31%)
Adenocarcinoma	116 (66%)	63 (55%)	75 (57%)	60 (49%)	314 (58%)
NSCLC NOS	16 (9%)	10 (9%)	10 (8%)	7 (6%)	43 (8%)
No histology	4 (2%)	5 (4%)	3 (2%)	5 (4%)	17 (3%)
Tumor diameter (cm)	2.4 (0.6; 5.0)	2.4 (1.0; 5.0)	2.5 (1.1; 4.9)	2.5 (0.8; 5.0)	2.5 (0.6; 5.0)
Prescribed radiation dose
45 Gy/3F	34 (19%)	22 (19%)	25 (19%)	22 (18%)	103 (19%)
66 Gy 3F	142 (81%)	93 (81%)	106 (81%)	100 (82%)	441 (81%)

^a One missing values.

^b Including one patient with PS = 4.

Table 2. Causes of death in patients with early-stage non-small lung cancer treated with SBRT.

	≤69 years N = 176	70–74 years N = 115	75–79 years N = 131	80 years N = 122	Total N = 544
Alive	89 (51%)	52 (45%)	60 (46%)	38 (31%)	239 (44%)
Lung cancer	38 (22%)	22 (19%)	28 (21%)	31 (25%)	119 (22%)
Other cancer	13 (%)	8 (%)	4 (3%)	8 (7%)	33 (5%)
Other causes	33 (18%)	29 (25%)	34 (26%)	43 (35%)	139 (26%)
Unknown cause	4 (2%)	4 (3%)	5 (4%)	2 (1%)	15 (3%)

Figure 1. (a) Overall survival after SBRT in early stage NSCLC. (b) Lung cancer specific survival after SBRT in early stage NSCLC.

Table 3. Overall survival: Cox proportional hazard analyses.

	HR	(95% CI)	p Value
Age (≤69/70–79/80+ year)^a	1.39	(1.18; 1.64)	.000
Charlson CI (≥3)	1.63	(1.29; 2.06)	.000
PS (≥2)	1.57	(1.24; 1.98)	.000
BMI (<18.5 kg/cm^2)	1.89	(1.32; 2.70)	.001
Tumor diameter (cm)	1.16	(1.03; 1.31)	.014
FEV1 (<50% of predicted)	1.34	(1.05; 1.70)	.018
Sex (male)	1.31	(1.03; 1.67)	.028

Nonsignificant factors with p > .10 included tumor dose (66 Gy), previous surgery, smoking within last year, adenocarcinoma histology.

^a Scored 1/2/3 in the model.